scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers grew its position in scPharmaceuticals Inc. (NASDAQ:SCPH) by 20.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 42,554 shares of the company’s stock after acquiring an additional 7,112 shares during the period. Rhumbline Advisers owned about 0.09% of scPharmaceuticals worth $151,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Legato Capital Management LLC acquired a new position in shares of scPharmaceuticals during the 4th quarter worth about $37,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of scPharmaceuticals during the 4th quarter worth about $38,000. SG Americas Securities LLC acquired a new position in shares of scPharmaceuticals during the 4th quarter worth about $66,000. Sanctuary Advisors LLC acquired a new position in shares of scPharmaceuticals during the 3rd quarter worth about $75,000. Finally, Virtu Financial LLC acquired a new position in shares of scPharmaceuticals during the 3rd quarter worth about $46,000. Institutional investors and hedge funds own 89.52% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on SCPH shares. Craig Hallum reduced their price target on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of scPharmaceuticals in a research report on Monday, March 3rd.

scPharmaceuticals Stock Down 1.4 %

Shares of NASDAQ SCPH opened at $2.89 on Tuesday. scPharmaceuticals Inc. has a 12-month low of $2.75 and a 12-month high of $6.20. The stock has a market cap of $144.62 million, a PE ratio of -1.52 and a beta of 0.40. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. The company has a 50-day moving average of $3.37 and a 200 day moving average of $3.91.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.